NCT02884700

Brief Summary

The study aimed at further describing the epidemiological, clinical, diagnostic and prognostic features in legionellosis cases admitted to Grenoble University Hospital during the 2006-2011period. The investigators also tested lower respiratory samples collected from these patients during their routine medical care, using a number of molecular tools allowing determination of the involved Legionella species, the bacterial load, and the presence of antibiotic resistant mutants. Our primary goal was to define biological markers that could predict severity and outcome of infection in legionellosis cases requiring hospitalization.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
82

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2009

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2009

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2011

Completed
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2014

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

August 22, 2016

Completed
9 days until next milestone

First Posted

Study publicly available on registry

August 31, 2016

Completed
Last Updated

August 31, 2016

Status Verified

August 1, 2016

Enrollment Period

2.2 years

First QC Date

August 22, 2016

Last Update Submit

August 30, 2016

Conditions

Keywords

LegionellaLegionnaires' diseaseDiagnosisPrognosis

Outcome Measures

Primary Outcomes (1)

  • Legionella DNA load in lower respiratory tract samples

    Real-time polymerase chain reaction (qPCR) dosages in lower respiratory tract samples collected on a routine basis all over the hospitalization duration

    through study completion, an average of 1 year

Secondary Outcomes (1)

  • Fluoroquinolones resistant gyrA mutants in lower respiratory tract samples

    through study completion, an average of 1 year

Study Arms (1)

Severe legionellosis cases

Patients admitted to Grenoble University Hospital for severe legionellosis between 2006 and 2011.

Biological: Real-time PCR testing of lower respiratory tract samples

Interventions

qPCR and high-throughput DNA sequencing testing of lower respiratory tract samples collected routinely in patients with severe legionellosis

Severe legionellosis cases

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

82 unrelated legionellosis cases 64 males, 18 females mean age: 55 years, range: 27-97 years severe legionellosis requiring hospitalization

You may qualify if:

  • age higher than 18 years
  • proven legionellosis case (positive culture and/or PCR and/or urinary antigen test)
  • severe case requiring hospitalization

You may not qualify if:

  • age under 18 years
  • pregnant women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITH DNA

Lower respiratory tract samples collected on a routine basis for microbiological analyses

MeSH Terms

Conditions

Legionnaires' DiseaseDisease

Condition Hierarchy (Ancestors)

LegionellosisGram-Negative Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfectionsRespiratory Tract InfectionsRespiratory Tract DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Hélène Sabbah-Guillaume, Director

    Direction of Research and Medical Innovation (DRCI)

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Pr. Max Maurin

Study Record Dates

First Submitted

August 22, 2016

First Posted

August 31, 2016

Study Start

September 1, 2009

Primary Completion

December 1, 2011

Study Completion

December 1, 2014

Last Updated

August 31, 2016

Record last verified: 2016-08

Data Sharing

IPD Sharing
Will not share

Biological data are available at the bacteriology laboratory. Clinical data are available at the participating medical wards.